Ndao Momar
National Reference Centre for Parasitology, Research Institute of the McGill University Health Centre, Montreal General Hospital, Montreal, QC, Canada.
Methods Mol Biol. 2012;818:67-79. doi: 10.1007/978-1-61779-418-6_5.
Proteins and peptides that undergo variations in concentration or state as a result of a biological process or disease may be used as biomarkers for the diagnosis or prognosis of diseases and/or for the monitoring of therapy. Serum/plasma is one of the most easily obtained patient specimens and contains thousands of proteins produced and secreted from cells and tissues. While serum/plasma is a valuable specimen for protein biomarker research, especially in the area of infectious diseases, the dynamic range of the proteome presents a technical challenge. Serum/plasma is dominated by high abundance proteins, such as albumin, immunoglobulins, haptogloblulin, which constitute almost 90% of the total serum/plasma protein by weight and make the detection of the low abundance proteins difficult. Therefore, effective fractionation and separation methods are essential to detect potential biomarker proteins present in small quantities for mass spectrometry.The current tests for blood-borne protozoan diseases are inadequate by monitoring treatment efficacy or for prognosis and also lack sensitivity and specificity. To overcome these limitations, we began a program to develop novel assays for infectious diseases using mass spectrometric data directly as well as "next generation" assays that exploit the richness of the MS data converted to standard platforms. Here we focus on high-throughput fractionation and proteomic analysis using Surface Enhanced Laser Desorption Ionization Time of Flight (SELDI-TOF) mass spectrometry platform. Separation and enrichment is achieved using stepwise anion exchange fractionation prior to analysis on multiple ProteinChip array chemistries. We have used this approach successfully to identify proteins/peptides or protein "profiles" (biomarkers) in subjects chronically infected with blood-borne protozoan parasites (i.e. Chagas disease, babesia, toxoplasma, malaria), fascioliosis, and cysticercosis.
由于生物过程或疾病而导致浓度或状态发生变化的蛋白质和肽,可被用作疾病诊断或预后以及/或者治疗监测的生物标志物。血清/血浆是最容易获取的患者样本之一,包含数千种由细胞和组织产生并分泌的蛋白质。虽然血清/血浆是蛋白质生物标志物研究的宝贵样本,尤其是在传染病领域,但蛋白质组的动态范围带来了技术挑战。血清/血浆中高丰度蛋白质占主导,如白蛋白、免疫球蛋白、触珠蛋白,按重量计它们几乎构成了血清/血浆总蛋白的90%,这使得低丰度蛋白质的检测变得困难。因此,有效的分级分离方法对于检测质谱分析中少量存在的潜在生物标志物蛋白质至关重要。目前针对血源原生动物疾病的检测在监测治疗效果或预后方面并不充分,而且缺乏敏感性和特异性。为了克服这些局限性,我们启动了一个项目,直接利用质谱数据以及利用转化为标准平台的质谱数据丰富性的“下一代”检测方法来开发针对传染病的新型检测方法。在这里,我们重点关注使用表面增强激光解吸电离飞行时间(SELDI - TOF)质谱平台进行高通量分级分离和蛋白质组分析。在对多种蛋白质芯片阵列化学物质进行分析之前,使用逐步阴离子交换分级分离实现分离和富集。我们已成功使用这种方法在慢性感染血源原生动物寄生虫(即恰加斯病、巴贝斯虫病、弓形虫病、疟疾)、肝片吸虫病和囊尾蚴病的受试者中鉴定出蛋白质/肽或蛋白质“谱”(生物标志物)。